The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review

MLA

Bao-Dong Qin, et al. “The Effectiveness of Afatinib and Osimertinib in a Chinese Patient with Advanced Lung Adenocarcinoma Harboring a Rare Triple EGFR Mutation (R670W/H835L/L833V): A Case Report and Literature Review.” OncoTargets and Therapy, vol. 11, Aug. 2018, pp. 4739–45. EBSCOhost, https://doi.org/10.2147/ott.s167346.

APA

Bao-Dong Qin, Wen-Xing Qin, Zhan Wang, Xiao-Dong Jiao, Ke Liu, Ling-Yan Yuan, & Yuan-Sheng Zang. (2018). The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review. OncoTargets and Therapy, 11, 4739–4745. https://doi.org/10.2147/ott.s167346

Chicago

Bao-Dong Qin, Wen-Xing Qin, Zhan Wang, Xiao-Dong Jiao, Ke Liu, Ling-Yan Yuan, and Yuan-Sheng Zang. 2018. “The Effectiveness of Afatinib and Osimertinib in a Chinese Patient with Advanced Lung Adenocarcinoma Harboring a Rare Triple EGFR Mutation (R670W/H835L/L833V): A Case Report and Literature Review.” OncoTargets and Therapy 11 (August): 4739–45. doi:10.2147/ott.s167346.